Table 6.

Ongoing studies assessing pharmacogenomics and antiplatelet therapy.

Study	Number of patients	Patient population	Therapy	Primary endpoint
GIFT	NA	All-comers undergoing PCI	Tailored clopidogrel versus standard clopidogrel according to platelet reactivity and genetic type	Residual platelet activity
TARGET-PCI	1,500	Nonemergent PCI	Tailored with clopidogrel and prasugrel to results of platelet reactivity and genetic type	MACE
CLOVIS-2	120	Post-MI	Clopidogrel 300 mg versus Clopidogrel 600 mg in 2 genetic CYP2C19 types	Inhibition of residual platelet activity 6 hours following clopidogrel
PREDICT	42	Stable CAD	Those with high residual platelet activity on clopidogrel and genotyped for CYP2C19 treated with double dose clopidogrel	Change in residual platelet activity
GeCCO	14,600	Recent ACS	Genotype-guided comparison of clopidogrel in extensive metabolizers and prasugrel	Cardiovascular death, nonfatal MI, or nonfatal stroke

GIFT: Genotype Information and Functional Testing; TARGET-PCI: Thrombocyte Activity Reassessment and Genotyping for PCI; CLOVIS-2: Clopidogrel and response Variability Investigation Study 2; PREDICT: Pilot Study on the Effect of High Clopidogrel Maintenance Dosing; GeCCO: Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study; PCI: percutaneous coronary intervention; MI: myocardial infarction; CAD: coronary artery disease; ACS: acute coronary syndrome; MACE: major adverse cardiovascular event.